Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 33Lymphoma 25Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Non-Hodgkin 12Leukemia 9Hodgkin Disease 9Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Multiple Myeloma 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Sarcoma 6Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Triple Negative Breast Neoplasms 5Neutropenia 5Lymphoma, B-Cell, Marginal Zone 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Prostatic Neoplasms 4Osteosarcoma 4Lung Neoplasms 4Waldenstrom Macroglobulinemia 3Testicular Neoplasms 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Neuroblastoma 3Neoplasm Metastasis 3

Interventions

Fulvestrant 5dalpiciclib 3Letrozole 3ribociclib 2palbociclib 2fluzoparib 2exemestane 2apatinib 2Anastrozole 2trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1irinotecan sucrosofate 1abemaciclib 1Zoledronic Acid 1Rogaratinib 1Patient Reported Outcome Measures 1Paclitaxel 1Neoadjuvant Therapy 1Liposomes 1Irinotecan 1Ga(III)-DOTATOC 1Everolimus 1Cell Separation 1Capecitabine 1Bevacizumab 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Cancer Metastatic × pegfilgrastim × Clear all
NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Samsung Medical Center

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡